Keros Net Tangible Assets vs Current Deferred Revenue Analysis
KROS Stock | USD 46.87 0.56 1.21% |
Keros TherapeuticsInc financial indicator trend analysis is infinitely more than just investigating Keros TherapeuticsInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Keros TherapeuticsInc is a good investment. Please check the relationship between Keros TherapeuticsInc Net Tangible Assets and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Keros Stock please use our How to Invest in Keros TherapeuticsInc guide.
Net Tangible Assets vs Current Deferred Revenue
Net Tangible Assets vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Keros TherapeuticsInc Net Tangible Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Keros TherapeuticsInc's Net Tangible Assets and Current Deferred Revenue is 0.43. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Keros TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of Keros TherapeuticsInc's Net Tangible Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Keros TherapeuticsInc are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Tangible Assets i.e., Keros TherapeuticsInc's Net Tangible Assets and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.43 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Keros TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Keros TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Keros Stock please use our How to Invest in Keros TherapeuticsInc guide.Sales General And Administrative To Revenue is likely to gain to 218.00 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 378K | 674K | 815K | 459.4K | Total Operating Expenses | 76.5M | 107.7M | 167.7M | 176.1M |
Keros TherapeuticsInc fundamental ratios Correlations
Click cells to compare fundamentals
Keros TherapeuticsInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Keros TherapeuticsInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 11.0M | 269.4M | 255.3M | 306.8M | 370.0M | 227.3M | |
Short Long Term Debt Total | 1.3M | 899K | 1.1M | 13.3M | 14.4M | 15.2M | |
Other Current Liab | 107K | 218K | 204K | 12.8M | 665K | 631.8K | |
Total Current Liabilities | 4.5M | 7.2M | 11.8M | 16.5M | 24.4M | 13.9M | |
Total Stockholder Equity | 5.5M | 261.7M | 243.2M | 277.4M | 332.2M | 207.7M | |
Net Tangible Assets | (19.4M) | 261.7M | 243.2M | 277.4M | 319.0M | 166.3M | |
Property Plant And Equipment Net | 1.9M | 1.6M | 2.4M | 17.6M | 19.5M | 20.4M | |
Current Deferred Revenue | 1.9M | 4.4M | 7.1M | 17.3M | 19.8M | 20.8M | |
Net Debt | (5.7M) | (265.0M) | (228.9M) | (265.8M) | (316.7M) | (300.9M) | |
Retained Earnings | (19.7M) | (65.0M) | (123.8M) | (228.4M) | (381.4M) | (362.4M) | |
Accounts Payable | 2.1M | 2.1M | 3.6M | 3.3M | 5.5M | 3.1M | |
Cash | 7.0M | 265.9M | 230.0M | 279.0M | 331.1M | 208.3M | |
Non Current Assets Total | 2.0M | 1.7M | 3.8M | 21.0M | 22.7M | 23.9M | |
Other Assets | 115K | 993K | 1.4M | 3.4M | 4.0M | 4.2M | |
Cash And Short Term Investments | 7.0M | 265.9M | 230.0M | 279.0M | 331.1M | 208.3M | |
Liabilities And Stockholders Equity | 11.0M | 269.4M | 255.3M | 306.8M | 370.0M | 227.3M | |
Non Current Liabilities Total | 1.0M | 538K | 231K | 12.8M | 13.4M | 14.1M | |
Capital Surpluse | 203K | 326.7M | 366.9M | 505.9M | 581.7M | 610.8M | |
Capital Lease Obligations | 1.3M | 899K | 1.1M | 13.3M | 14.4M | 15.2M | |
Other Current Assets | 226K | 160K | 340K | 6.7M | 1.0M | 1.6M | |
Other Stockholder Equity | 25.1M | 326.7M | 366.9M | 505.9M | 713.6M | 749.3M | |
Total Liab | 5.5M | 7.7M | 12.1M | 29.4M | 37.8M | 19.6M | |
Net Invested Capital | 5.5M | 261.7M | 243.2M | 277.4M | 332.2M | 204.0M | |
Property Plant And Equipment Gross | 1.9M | 1.6M | 2.4M | 17.6M | 21.2M | 22.2M | |
Total Current Assets | 8.9M | 267.7M | 251.4M | 285.8M | 347.3M | 217.6M | |
Non Current Liabilities Other | 119K | 62K | 231K | 12.8M | 14.7M | 15.5M | |
Net Working Capital | 4.4M | 260.5M | 239.6M | 269.2M | 322.9M | 203.6M | |
Short Term Debt | 376K | 423K | 862K | 455K | 1.0M | 602.6K | |
Property Plant Equipment | 1.9M | 1.6M | 1.3M | 2.0M | 2.3M | 1.8M |
Pair Trading with Keros TherapeuticsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Keros TherapeuticsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Keros TherapeuticsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Keros Stock
0.89 | EQ | Equillium | PairCorr |
Moving against Keros Stock
0.66 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Keros TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Keros TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Keros TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Keros TherapeuticsInc to buy it.
The correlation of Keros TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Keros TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Keros TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Keros TherapeuticsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Keros Stock please use our How to Invest in Keros TherapeuticsInc guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Keros Stock analysis
When running Keros TherapeuticsInc's price analysis, check to measure Keros TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros TherapeuticsInc is operating at the current time. Most of Keros TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Keros TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros TherapeuticsInc's price. Additionally, you may evaluate how the addition of Keros TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
CEOs Directory Screen CEOs from public companies around the world | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Keros TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Keros TherapeuticsInc. If investors know Keros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Keros TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.15) | Revenue Per Share 0.007 | Return On Assets (0.26) | Return On Equity (0.40) |
The market value of Keros TherapeuticsInc is measured differently than its book value, which is the value of Keros that is recorded on the company's balance sheet. Investors also form their own opinion of Keros TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Keros TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Keros TherapeuticsInc's market value can be influenced by many factors that don't directly affect Keros TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Keros TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Keros TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Keros TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.